Macquarie Group LTD Apellis Pharmaceuticals, Inc. Transaction History

Macquarie Group LTD

$86.4 Billion
Q4 2024

A detailed history of Macquarie Group LTD transactions in Apellis Pharmaceuticals, Inc. stock. As of the latest transaction made, Macquarie Group LTD holds 201,067 shares of APLS stock, worth $5.7 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

201,067

Previous 183,289 9.7%

Holding current value

$5.7 Million

Previous $5.29 Million 21.38%

% of portfolio

0.01%

Previous 0.01%

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	BUY	$26.18 - $35.42 $465,428 - $629,696	17,778 Added 9.7%	201,067 $6.42 Million
Q3 2024 Nov 14, 2024	SELL	$28.84 - $41.15 $47,355 - $67,568	-1,642 Reduced 0.89%	183,289 $5.29 Million
Q2 2024 Aug 09, 2024	SELL	$38.07 - $59.71 $1.4 Million - $2.19 Million	-36,723 Reduced 16.57%	184,931 $7.09 Million
Q1 2024 May 14, 2024	SELL	$55.39 - $72.47 $20 Million - $26.2 Million	-361,775 Reduced 62.01%	221,654 $13 Million
Q4 2023 Feb 14, 2024	SELL	$37.14 - $64.82 $18.3 Million - $32 Million	-493,119 Reduced 45.81%	583,429 $34.9 Million
Q3 2023 Nov 14, 2023	BUY	$23.65 - $89.22 $7.12 Million - $26.9 Million	301,068 Added 38.82%	1,076,548 $41 Million
Q2 2023 Aug 14, 2023	SELL	$76.68 - $93.31 $48.8 Million - $59.3 Million	-635,999 Reduced 45.06%	775,480 $70.6 Million
Q1 2023 May 15, 2023	SELL	$46.59 - $66.96 $2.34 Million - $3.36 Million	-50,163 Reduced 3.43%	1,411,479 $93.1 Million
Q4 2022 Feb 21, 2023	BUY	$43.24 - $61.04 $1.73 Million - $2.45 Million	40,107 Added 2.82%	1,461,642 $75.6 Million
Q3 2022 Nov 14, 2022	BUY	$44.76 - $69.66 $1.7 Million - $2.65 Million	38,028 Added 2.75%	1,421,535 $97.2 Million
Q2 2022 Aug 15, 2022	BUY	$35.07 - $59.21 $2.17 Million - $3.67 Million	61,949 Added 4.69%	1,383,507 $62.6 Million
Q1 2022 May 16, 2022	BUY	$35.46 - $54.12 $1.06 Million - $1.61 Million	29,775 Added 2.3%	1,321,558 $67.1 Million
Q4 2021 Feb 11, 2022	BUY	$30.74 - $49.16 $5.28 Million - $8.44 Million	171,693 Added 15.33%	1,291,783 $61.1 Million
Q3 2021 Nov 12, 2021	BUY	$31.4 - $69.84 $18 Million - $40.1 Million	574,416 Added 105.27%	1,120,090 $36.9 Million
Q2 2021 Aug 13, 2021	BUY	$40.9 - $64.9 $22.2 Million - $35.3 Million	543,529 Added 25339.35%	545,674 $34.5 Million
Q1 2021 May 14, 2021	SELL	$40.8 - $57.39 $29,253 - $41,148	-717 Reduced 25.05%	2,145 $92,000
Q2 2020 Aug 11, 2020	BUY	$24.8 - $38.49 $70,977 - $110,158	2,862 New	2,862 $93,000

Others Institutions Holding APLS

# of Institutions

302

Shares Held

123M

Call Options Held

2.63M

Put Options Held

845K

View Full List

About Apellis Pharmaceuticals, Inc.

Ticker APLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 109,865,000
Market Cap $3.11B
Description
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...

More about APLS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Macquarie Group LTD, based on Form 13F filings with the SEC.

News

Stay updated on Macquarie Group LTD with notifications on news.

Account

Macquarie Group LTD Apellis Pharmaceuticals, Inc. Transaction History